BioNexus Gene Lab Corp. (BGLC) announced the execution of an Exclusive Intellectual Property License Agreement with Fidelion Diagnostics Pte. Ltd. for the VitaGuard™ MRD platform in Southeast Asia.
The license agreement grants BGLC exclusive, perpetual rights to develop, manufacture, market, and distribute VitaGuard-based products and services in Southeast Asia.
BGLC will pay Fidelion a US$2 million license fee in 24 monthly instalments and commit to at least US$500,000 of VitaGuard reagent and system purchases in the first 24 months.
Exclusive License in Southeast Asia
BGLC secures exclusive, perpetual rights to the VitaGuard™ MRD platform in Southeast Asia through the agreement with Fidelion Diagnostics.
Financial Commitment
The agreement includes a US$2 million license fee payment and a commitment to purchase US$500,000 of VitaGuard reagents and systems.
Strategic Partnership
The agreement is part of the broader equity alliance with Fidelion and Tongshu Gene, aiming to drive MRD testing into routine care.
- The global liquid biopsy market is expected to grow significantly, with the MRD testing segment showing rapid expansion from research to routine clinical practice.
- Commercially, leading MRD providers are processing hundreds of thousands of oncology tests per year, indicating the adoption of MRD blood tests in advanced markets.
- Southeast Asia's cancer burden is substantial and increasing, creating a significant opportunity for MRD testing and early cancer detection in the region.
The execution of the exclusive license agreement marks a strategic step for BGLC in advancing MRD testing in Southeast Asia, aligning with the growing trends in the liquid biopsy market and the region's healthcare needs.